These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35004270)

  • 1. Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report.
    Wang X; Peng W; Zeng Z; Cai J; Liu A
    Front Oncol; 2021; 11():720819. PubMed ID: 35004270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel
    Sun Y; Pei L; Luo N; Chen D; Meng L
    Onco Targets Ther; 2020; 13():11177-11181. PubMed ID: 33173309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two case reports of non-small cell lung cancer patients harboring acquired
    Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
    Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation.
    Chen J; Wu X; Wang J
    Front Oncol; 2022; 12():898586. PubMed ID: 35957876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon
    Ou L; Tang Y; Deng Y; Guo L; He Q; He T; Feng W
    Front Oncol; 2022; 12():911362. PubMed ID: 35957915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report.
    Liu B; Qin J; Yin Y; Zhai L; Liu G; Lizaso A; Shi D
    Ann Transl Med; 2021 Jan; 9(1):80. PubMed ID: 33553373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer.
    Liu Z; Dong H; Chen W; Wang B; Ji D; Zhang W; Shi X; Feng X
    Front Med (Lausanne); 2022; 9():906364. PubMed ID: 35872785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib.
    Wang Y; Han R; Zhu M; He T; He Y
    Front Oncol; 2022; 12():875313. PubMed ID: 35530305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation.
    Zhu Y; Tang J; Li X; Qin T; Wei Y
    Onco Targets Ther; 2020; 13():10447-10451. PubMed ID: 33116624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and
    Zhao J; Zou M; Lv J; Han Y; Wang G; Wang G
    Onco Targets Ther; 2018; 11():5545-5550. PubMed ID: 30233215
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ma L; Chen R; Wang F; Ma LL; Yuan MM; Chen RR; Liu J
    Ann Transl Med; 2019 May; 7(9):207. PubMed ID: 31205925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report.
    Chen Y; Meng C; Liu K; Liu L; Mo R; Chen S; Xie S; Xiang J
    Transl Cancer Res; 2020 May; 9(5):3750-3754. PubMed ID: 35117738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.
    Shen Q; Qu J; Chen Z; Zhou J
    Front Oncol; 2021; 11():760097. PubMed ID: 34926262
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
    Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of afatinib in an NSCLC patient with
    Nozaki K; Watanabe S; Nishio K; Sakai K; Kikuchi T
    Transl Cancer Res; 2022 Jan; 11(1):295-298. PubMed ID: 35261905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
    Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
    J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
    Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
    Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.